Will Oklo Stock Double?
Oklo (NYSE: OKLO) is only a year removed from its SPAC‑enabled debut,…
Buy
70
IDNA Quote, Financials, Valuation and Earnings
Last price:
$21.45
Seasonality move
:
-5.13%
Day range:
$21.15 - $21.43
52-week range:
$17.26 - $25.80
Dividend yield:
1.25%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
--
Volume:
84K
Avg. volume:
32.5K
1-year change:
-12.92%
Market cap:
--
Revenue:
--
EPS (TTM):
--
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
IDNA
iShares Genomics Immunology and Healthcare ETF
|
-- | -- | -- | -- | -- |
|
BBH
VanEck Biotech ETF
|
-- | -- | -- | -- | -- |
|
FXH
First Trust Health Care AlphaDEX Fund
|
-- | -- | -- | -- | -- |
|
GRX
Gabelli Healthcare & WellnessRx Trust
|
-- | -- | -- | -- | -- |
|
IHE
iShares US Pharmaceuticals ETF
|
-- | -- | -- | -- | -- |
|
PJP
Invesco Pharmaceuticals ETF
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
IDNA
iShares Genomics Immunology and Healthcare ETF
|
$21.19 | -- | -- | -- | $0.15 | 1.25% | -- |
|
BBH
VanEck Biotech ETF
|
$158.22 | -- | -- | -- | $1.25 | 0.79% | -- |
|
FXH
First Trust Health Care AlphaDEX Fund
|
$102.23 | -- | -- | -- | $0.06 | 0.34% | -- |
|
GRX
Gabelli Healthcare & WellnessRx Trust
|
$9.38 | -- | -- | -- | $0.17 | 6.61% | -- |
|
IHE
iShares US Pharmaceuticals ETF
|
$67.18 | -- | -- | -- | $0.31 | 1.74% | -- |
|
PJP
Invesco Pharmaceuticals ETF
|
$82.48 | -- | -- | -- | $0.27 | 1.17% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
IDNA
iShares Genomics Immunology and Healthcare ETF
|
-- | 0.832 | -- | -- |
|
BBH
VanEck Biotech ETF
|
-- | 0.630 | -- | -- |
|
FXH
First Trust Health Care AlphaDEX Fund
|
-- | 0.984 | -- | -- |
|
GRX
Gabelli Healthcare & WellnessRx Trust
|
-- | 0.575 | -- | -- |
|
IHE
iShares US Pharmaceuticals ETF
|
-- | 0.333 | -- | -- |
|
PJP
Invesco Pharmaceuticals ETF
|
-- | 0.248 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
IDNA
iShares Genomics Immunology and Healthcare ETF
|
-- | -- | -- | -- | -- | -- |
|
BBH
VanEck Biotech ETF
|
-- | -- | -- | -- | -- | -- |
|
FXH
First Trust Health Care AlphaDEX Fund
|
-- | -- | -- | -- | -- | -- |
|
GRX
Gabelli Healthcare & WellnessRx Trust
|
-- | -- | -- | -- | -- | -- |
|
IHE
iShares US Pharmaceuticals ETF
|
-- | -- | -- | -- | -- | -- |
|
PJP
Invesco Pharmaceuticals ETF
|
-- | -- | -- | -- | -- | -- |
iShares Genomics Immunology and Healthcare ETF vs. Competitors
-
Which has Higher Returns IDNA or BBH?
VanEck Biotech ETF has a net margin of -- compared to iShares Genomics Immunology and Healthcare ETF's net margin of --. iShares Genomics Immunology and Healthcare ETF's return on equity of -- beat VanEck Biotech ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital IDNAiShares Genomics Immunology and Healthcare ETF-- -- -- BBHVanEck Biotech ETF-- -- -- -
What do Analysts Say About IDNA or BBH?
iShares Genomics Immunology and Healthcare ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand VanEck Biotech ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that iShares Genomics Immunology and Healthcare ETF has higher upside potential than VanEck Biotech ETF, analysts believe iShares Genomics Immunology and Healthcare ETF is more attractive than VanEck Biotech ETF.
Company Buy Ratings Hold Ratings Sell Ratings IDNAiShares Genomics Immunology and Healthcare ETF0 0 0 BBHVanEck Biotech ETF0 0 0 -
Is IDNA or BBH More Risky?
iShares Genomics Immunology and Healthcare ETF has a beta of 1.048, which suggesting that the stock is 4.758% more volatile than S&P 500. In comparison VanEck Biotech ETF has a beta of 0.764, suggesting its less volatile than the S&P 500 by 23.586%.
-
Which is a Better Dividend Stock IDNA or BBH?
iShares Genomics Immunology and Healthcare ETF has a quarterly dividend of $0.15 per share corresponding to a yield of 1.25%. VanEck Biotech ETF offers a yield of 0.79% to investors and pays a quarterly dividend of $1.25 per share. iShares Genomics Immunology and Healthcare ETF pays -- of its earnings as a dividend. VanEck Biotech ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IDNA or BBH?
iShares Genomics Immunology and Healthcare ETF quarterly revenues are --, which are smaller than VanEck Biotech ETF quarterly revenues of --. iShares Genomics Immunology and Healthcare ETF's net income of -- is lower than VanEck Biotech ETF's net income of --. Notably, iShares Genomics Immunology and Healthcare ETF's price-to-earnings ratio is -- while VanEck Biotech ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for iShares Genomics Immunology and Healthcare ETF is -- versus -- for VanEck Biotech ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IDNAiShares Genomics Immunology and Healthcare ETF-- -- -- -- BBHVanEck Biotech ETF-- -- -- --
-
Which has Higher Returns IDNA or FXH?
First Trust Health Care AlphaDEX Fund has a net margin of -- compared to iShares Genomics Immunology and Healthcare ETF's net margin of --. iShares Genomics Immunology and Healthcare ETF's return on equity of -- beat First Trust Health Care AlphaDEX Fund's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital IDNAiShares Genomics Immunology and Healthcare ETF-- -- -- FXHFirst Trust Health Care AlphaDEX Fund-- -- -- -
What do Analysts Say About IDNA or FXH?
iShares Genomics Immunology and Healthcare ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand First Trust Health Care AlphaDEX Fund has an analysts' consensus of -- which suggests that it could fall by --. Given that iShares Genomics Immunology and Healthcare ETF has higher upside potential than First Trust Health Care AlphaDEX Fund, analysts believe iShares Genomics Immunology and Healthcare ETF is more attractive than First Trust Health Care AlphaDEX Fund.
Company Buy Ratings Hold Ratings Sell Ratings IDNAiShares Genomics Immunology and Healthcare ETF0 0 0 FXHFirst Trust Health Care AlphaDEX Fund0 0 0 -
Is IDNA or FXH More Risky?
iShares Genomics Immunology and Healthcare ETF has a beta of 1.048, which suggesting that the stock is 4.758% more volatile than S&P 500. In comparison First Trust Health Care AlphaDEX Fund has a beta of 0.785, suggesting its less volatile than the S&P 500 by 21.471%.
-
Which is a Better Dividend Stock IDNA or FXH?
iShares Genomics Immunology and Healthcare ETF has a quarterly dividend of $0.15 per share corresponding to a yield of 1.25%. First Trust Health Care AlphaDEX Fund offers a yield of 0.34% to investors and pays a quarterly dividend of $0.06 per share. iShares Genomics Immunology and Healthcare ETF pays -- of its earnings as a dividend. First Trust Health Care AlphaDEX Fund pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IDNA or FXH?
iShares Genomics Immunology and Healthcare ETF quarterly revenues are --, which are smaller than First Trust Health Care AlphaDEX Fund quarterly revenues of --. iShares Genomics Immunology and Healthcare ETF's net income of -- is lower than First Trust Health Care AlphaDEX Fund's net income of --. Notably, iShares Genomics Immunology and Healthcare ETF's price-to-earnings ratio is -- while First Trust Health Care AlphaDEX Fund's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for iShares Genomics Immunology and Healthcare ETF is -- versus -- for First Trust Health Care AlphaDEX Fund. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IDNAiShares Genomics Immunology and Healthcare ETF-- -- -- -- FXHFirst Trust Health Care AlphaDEX Fund-- -- -- --
-
Which has Higher Returns IDNA or GRX?
Gabelli Healthcare & WellnessRx Trust has a net margin of -- compared to iShares Genomics Immunology and Healthcare ETF's net margin of --. iShares Genomics Immunology and Healthcare ETF's return on equity of -- beat Gabelli Healthcare & WellnessRx Trust's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital IDNAiShares Genomics Immunology and Healthcare ETF-- -- -- GRXGabelli Healthcare & WellnessRx Trust-- -- -- -
What do Analysts Say About IDNA or GRX?
iShares Genomics Immunology and Healthcare ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Gabelli Healthcare & WellnessRx Trust has an analysts' consensus of -- which suggests that it could fall by --. Given that iShares Genomics Immunology and Healthcare ETF has higher upside potential than Gabelli Healthcare & WellnessRx Trust, analysts believe iShares Genomics Immunology and Healthcare ETF is more attractive than Gabelli Healthcare & WellnessRx Trust.
Company Buy Ratings Hold Ratings Sell Ratings IDNAiShares Genomics Immunology and Healthcare ETF0 0 0 GRXGabelli Healthcare & WellnessRx Trust0 0 0 -
Is IDNA or GRX More Risky?
iShares Genomics Immunology and Healthcare ETF has a beta of 1.048, which suggesting that the stock is 4.758% more volatile than S&P 500. In comparison Gabelli Healthcare & WellnessRx Trust has a beta of 0.995, suggesting its less volatile than the S&P 500 by 0.513%.
-
Which is a Better Dividend Stock IDNA or GRX?
iShares Genomics Immunology and Healthcare ETF has a quarterly dividend of $0.15 per share corresponding to a yield of 1.25%. Gabelli Healthcare & WellnessRx Trust offers a yield of 6.61% to investors and pays a quarterly dividend of $0.17 per share. iShares Genomics Immunology and Healthcare ETF pays -- of its earnings as a dividend. Gabelli Healthcare & WellnessRx Trust pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IDNA or GRX?
iShares Genomics Immunology and Healthcare ETF quarterly revenues are --, which are smaller than Gabelli Healthcare & WellnessRx Trust quarterly revenues of --. iShares Genomics Immunology and Healthcare ETF's net income of -- is lower than Gabelli Healthcare & WellnessRx Trust's net income of --. Notably, iShares Genomics Immunology and Healthcare ETF's price-to-earnings ratio is -- while Gabelli Healthcare & WellnessRx Trust's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for iShares Genomics Immunology and Healthcare ETF is -- versus -- for Gabelli Healthcare & WellnessRx Trust. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IDNAiShares Genomics Immunology and Healthcare ETF-- -- -- -- GRXGabelli Healthcare & WellnessRx Trust-- -- -- --
-
Which has Higher Returns IDNA or IHE?
iShares US Pharmaceuticals ETF has a net margin of -- compared to iShares Genomics Immunology and Healthcare ETF's net margin of --. iShares Genomics Immunology and Healthcare ETF's return on equity of -- beat iShares US Pharmaceuticals ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital IDNAiShares Genomics Immunology and Healthcare ETF-- -- -- IHEiShares US Pharmaceuticals ETF-- -- -- -
What do Analysts Say About IDNA or IHE?
iShares Genomics Immunology and Healthcare ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand iShares US Pharmaceuticals ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that iShares Genomics Immunology and Healthcare ETF has higher upside potential than iShares US Pharmaceuticals ETF, analysts believe iShares Genomics Immunology and Healthcare ETF is more attractive than iShares US Pharmaceuticals ETF.
Company Buy Ratings Hold Ratings Sell Ratings IDNAiShares Genomics Immunology and Healthcare ETF0 0 0 IHEiShares US Pharmaceuticals ETF0 0 0 -
Is IDNA or IHE More Risky?
iShares Genomics Immunology and Healthcare ETF has a beta of 1.048, which suggesting that the stock is 4.758% more volatile than S&P 500. In comparison iShares US Pharmaceuticals ETF has a beta of 0.574, suggesting its less volatile than the S&P 500 by 42.647%.
-
Which is a Better Dividend Stock IDNA or IHE?
iShares Genomics Immunology and Healthcare ETF has a quarterly dividend of $0.15 per share corresponding to a yield of 1.25%. iShares US Pharmaceuticals ETF offers a yield of 1.74% to investors and pays a quarterly dividend of $0.31 per share. iShares Genomics Immunology and Healthcare ETF pays -- of its earnings as a dividend. iShares US Pharmaceuticals ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IDNA or IHE?
iShares Genomics Immunology and Healthcare ETF quarterly revenues are --, which are smaller than iShares US Pharmaceuticals ETF quarterly revenues of --. iShares Genomics Immunology and Healthcare ETF's net income of -- is lower than iShares US Pharmaceuticals ETF's net income of --. Notably, iShares Genomics Immunology and Healthcare ETF's price-to-earnings ratio is -- while iShares US Pharmaceuticals ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for iShares Genomics Immunology and Healthcare ETF is -- versus -- for iShares US Pharmaceuticals ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IDNAiShares Genomics Immunology and Healthcare ETF-- -- -- -- IHEiShares US Pharmaceuticals ETF-- -- -- --
-
Which has Higher Returns IDNA or PJP?
Invesco Pharmaceuticals ETF has a net margin of -- compared to iShares Genomics Immunology and Healthcare ETF's net margin of --. iShares Genomics Immunology and Healthcare ETF's return on equity of -- beat Invesco Pharmaceuticals ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital IDNAiShares Genomics Immunology and Healthcare ETF-- -- -- PJPInvesco Pharmaceuticals ETF-- -- -- -
What do Analysts Say About IDNA or PJP?
iShares Genomics Immunology and Healthcare ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Invesco Pharmaceuticals ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that iShares Genomics Immunology and Healthcare ETF has higher upside potential than Invesco Pharmaceuticals ETF, analysts believe iShares Genomics Immunology and Healthcare ETF is more attractive than Invesco Pharmaceuticals ETF.
Company Buy Ratings Hold Ratings Sell Ratings IDNAiShares Genomics Immunology and Healthcare ETF0 0 0 PJPInvesco Pharmaceuticals ETF0 0 0 -
Is IDNA or PJP More Risky?
iShares Genomics Immunology and Healthcare ETF has a beta of 1.048, which suggesting that the stock is 4.758% more volatile than S&P 500. In comparison Invesco Pharmaceuticals ETF has a beta of 0.502, suggesting its less volatile than the S&P 500 by 49.771%.
-
Which is a Better Dividend Stock IDNA or PJP?
iShares Genomics Immunology and Healthcare ETF has a quarterly dividend of $0.15 per share corresponding to a yield of 1.25%. Invesco Pharmaceuticals ETF offers a yield of 1.17% to investors and pays a quarterly dividend of $0.27 per share. iShares Genomics Immunology and Healthcare ETF pays -- of its earnings as a dividend. Invesco Pharmaceuticals ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IDNA or PJP?
iShares Genomics Immunology and Healthcare ETF quarterly revenues are --, which are smaller than Invesco Pharmaceuticals ETF quarterly revenues of --. iShares Genomics Immunology and Healthcare ETF's net income of -- is lower than Invesco Pharmaceuticals ETF's net income of --. Notably, iShares Genomics Immunology and Healthcare ETF's price-to-earnings ratio is -- while Invesco Pharmaceuticals ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for iShares Genomics Immunology and Healthcare ETF is -- versus -- for Invesco Pharmaceuticals ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IDNAiShares Genomics Immunology and Healthcare ETF-- -- -- -- PJPInvesco Pharmaceuticals ETF-- -- -- --
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why a $5 Stock Is Suddenly a Cash Machine
If you stopped tracking Grab Holdings (NASDAQ: GRAB) after its 2021 SPAC…
Is Roku Stock Undervalued Now?
At roughly $89 a share, Roku (NASDAQ: ROKU) trades for barely…
Stock Ideas
Buy
69
Is NVDA Stock a Buy?
Market Cap: $4T
P/E Ratio: 56x
Buy
62
Is MSFT Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 43x
Sell
45
Is AAPL Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 35x
Alerts
Buy
58
INKT alert for Jul 14
MiNK Therapeutics [INKT] is down 36.03% over the past day.
Buy
51
NEGG alert for Jul 14
Newegg Commerce [NEGG] is down 26.42% over the past day.
Buy
68
ATRO alert for Jul 14
Astronics [ATRO] is down 1.02% over the past day.
